Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

XOMA Corp XOMA

Healthcare Biotechnology
XOMA Corporation is a biotechnology royalty aggregator. The Company’s royalty aggregator business is primarily focused on early to mid-stage clinical assets, primarily in Phase I and II, with significant commercial sales potential that are licensed to larger pharmaceutical partners. The Company has a portfolio of economic rights and royalty payments associated with partnered commercial and pre-commercial therapeutic candidates. Its royalty portfolio includes DAY101 (tovorafenib), JNJ-63723283 (cetrelimab), RZ358, arimoclomol, TAK-079 (mezagitamab), BAY-1213790 (osocimab), AFM13 (acimtamig), AB023 (gruticibart), AB002 (E-WE thrombin), AB054, AV-299 (ficlatuzumab), COM902, vosaroxin, aldoxorubicin, INCAGN2385, INCAGN02390, MNPR-101, PBF-680, PBF-677, PBF-999, PBF-1129, PBF-1650, G03-52-01, RZ402, DSUVIA (sufentanil sublingual tablet), IXINITY [coagulation factor IX (recombinant)], VABYSMO (faricimab-svoa), CMP-001 (vidutolimod), and CFZ533 (iscalimab).


NDAQ:XOMA - Post by User

XOMA Corp
Bullboard Posts
User Avatar Image
(0)
•••
Post by battlinal74on May 28, 2002 6:50am
133 Views
Post# 5152747

XOMA is the focus stock today at Chartplays

XOMA is the focus stock today at ChartplaysXOMA is reviewed as the focus free chart of the day at Chartplays.com today. According to the people at Chartplays.com, XOMA is showing some technical evidence that it could be a buy today. Their info on why and where is pretty good stuff. I look for free sites that give an independent analysis of a stock. If anyone knows of any please let me know.
Bullboard Posts
Dealroom for high-potential pre-IPO opportunities